Key Stats for HIMS Stock
- YTD Price Change for HIMS stock: 36%
- $HIMS Share Price as of Dec. 26: $584
- 52-Week High: $886
- $HIMS Stock Price Target: $820
Now Live: Discover how much upside your favorite stocks could have using TIKR’s new Valuation Model (It’s free)>>>
What Happened?
Hims & Hers (HIMS) stock has been one of the standout performers of 2025, climbing 36% year-to-date and, at one point, surging over 80% from the start of the year.
The telehealth company has capitalized on explosive demand in the weight loss market while continuing to expand its broader health platform.
The company’s third-quarter results showed why investors are excited. Revenue jumped 49% year-over-year to $599 million, beating guidance and analyst expectations.
More importantly, Hims & Hers grew its subscriber base by 21% to 2.47 million customers, with revenue per subscriber climbing 19% to $80 per month in Q3 of 2025.
The real story is in personalized treatments. Customers using at least one personalized subscription soared 80% to 1.6 million, representing over 65% of the subscriber base.
These personalized offerings deliver higher retention rates and better margins than the company’s legacy one-off treatments.
But the most significant catalyst for HIMS stock came from its weight loss business. The company has aggressively entered the GLP-1 market, offering compounded versions of the active ingredients found in blockbuster drugs such as Ozempic and Wegovy.
When branded drug shortages created an opening, Hims & Hers jumped in with affordable alternatives that gained rapid traction.
See analysts’ growth forecasts and price targets for HIMS stock (It’s free!) >>>
What the Market Is Telling Us About HIMS Stock
The company isn’t resting on its weight loss success. Management launched new specialties in 2025, including menopause support and low testosterone treatments, both targeting massive underserved markets.
CFO Yemi Okupe noted that the Hers brand is on track to hit $1 billion in revenue in 2026, driven by triple-digit growth rates.
The fourth quarter announcement of comprehensive whole-body lab testing marks another evolution. CEO Andrew Dudum explained that historically, people came to Hims & Hers to treat existing conditions.
Now, the company plans to help customers proactively manage their health before problems even arise. This shift from reactive to proactive care could fundamentally change how investors value the platform.
Despite the strong performance, HIMS stock hasn’t been without volatility. Gross margins fell 500 basis points year-over-year to 74% in the third quarter as the company transitioned weight loss fulfillment to smaller shipment cadences.
Management expects about $20 million to $25 million in headwinds from this shift in Q4, though the impact should normalize in the second half of 2026.
The company also announced it would pause year-over-year margin expansion as it invests heavily in new categories, international expansion, and technology infrastructure.
Management plans to enter Canada, deepen its presence in the U.K., and expand into Brazil, Australia, and other markets. The recent acquisition of Zava has already given Hims & Hers access to over 200 million adults across the U.K., Germany, France, Ireland, and Spain.
For the full year, management guided revenue between $2.335 billion and $2.355 billion, representing 58% to 59% growth.
Adjusted EBITDA is expected to hit $307 million to $317 million, or about 13% margins at the midpoint.
While margins are compressing in the near term due to investments, the company reiterated its ambitious 2030 targets of $6.5 billion in revenue and $1.3 billion in adjusted EBITDA.
Multiple firms have named HIMS stock a top pick for 2025, upgrading price targets and highlighting the company’s attractive risk-reward profile. Institutional investors have piled in as well, signaling confidence in management’s execution.
The bull case for HIMS stock is straightforward: the company is building a comprehensive digital health platform that serves customers across their entire health journey.
Weight loss may have captured headlines, but the real opportunity is in becoming the default destination for personalized, convenient care across dozens of conditions.
If management can execute on that vision while continuing to verticalize operations and expand internationally, today’s valuation could look cheap in hindsight.
Estimate a company’s fair value instantly (Free with TIKR) >>>
How Much Upside Does HIMS Stock Have From Here?
With TIKR’s new Valuation Model tool, you can estimate a stock’s potential share price in under a minute.
All it takes is three simple inputs:
- Revenue Growth
- Operating Margins
- Exit P/E Multiple
If you’re not sure what to enter, TIKR automatically fills in each input using analysts’ consensus estimates, giving you a quick, reliable starting point.
From there, TIKR calculates the potential share price and total returns under Bull, Base, and Bear scenarios so you can quickly see whether a stock looks undervalued or overvalued.
See a stock’s true value in under 60 seconds (Free with TIKR) >>>
Looking for New Opportunities?
- See what stocks billionaire investors are buying so you can follow the smart money.
- Analyze stocks in as little as 5 minutes with TIKR’s all-in-one, easy-to-use platform.
- The more rocks you overturn… the more opportunities you’ll uncover. Search 100K+ global stocks, global top investor holdings, and more with TIKR.
Disclaimer:
Please note that the articles on TIKR are not intended to serve as investment or financial advice from TIKR or our content team, nor are they recommendations to buy or sell any stocks. We create our content based on TIKR Terminal’s investment data and analysts’ estimates. Our analysis might not include recent company news or important updates. TIKR has no position in any stocks mentioned. Thank you for reading, and happy investing!
